Result destination
PACS and workstation are explicitly referenced as a result destination.
exact submission · checked 2026-09-01Confirm supported products, versions, routing behavior, and display requirements during local evaluation.
FDA-cleared profile
CogNet QmTRIAGE
MedCognetics, Inc.
Authorized purpose: Passive exam-level notification and prioritization of suspicious findings in screening mammograms.
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.
Product overview
Start with the essentials
Authorized purpose: Passive exam-level notification and prioritization of suspicious findings in screening mammograms.
Overview status: Source-reviewed overview
- What does this software do? Authorized purpose: Passive exam-level notification and prioritization of suspicious findings in screening mammograms.
- Which images or clinical context are in scope? Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Complete 2D FFDM screening mammography exams acquired on validated FFDM systems.
- Who uses it? Intended users: MQSA-qualified interpreting physicians.
- What does the software produce? Output: Exam-level PACS/workstation flagging for worklist prioritization; no diagnostic information and no image removal.
- What is its most important limitation? Key limitation: Not diagnostic or a substitute for full evaluation; DBT images and 2D synthetic views are excluded; exact broader device compatibility is unknown.
Clinical takeaway
Clinical role: Passive exam-level notification and prioritization of suspicious findings in screening mammograms.
Evidence takeaway
Evidence from the reviewed source record: FDA packet reports 800 retrospective anonymized 2D FFDM exams, 399 biopsy-proven cancer and 401 negative BI-RADS 1/2 cases; AUROC 0.9569 (95% CI 0.9364-0.9738), sensitivity 87%, and specificity 89%. Accuracy 95.6% is not reported.
Clinical details
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
- Exact purpose
- Passive exam-level notification and prioritization of suspicious findings in screening mammograms.
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
- Intended users
- MQSA-qualified interpreting physicians.
FDA indications statement.
- Care setting and population
- The screening population described in the FDA intended use; the institutional care setting requires local confirmation.
Conservative normalization of explicit wording in an exact-submission source.
- Workflow role
- Triage or notification support
Conservative normalization of explicit wording in an exact-submission source.
- Required input
- Complete 2D FFDM screening mammography exams acquired on validated FFDM systems.
FDA indications statement.
- Output and human action
- Exam-level PACS/workstation flagging for worklist prioritization; no diagnostic information and no image removal.
FDA intended-use and technological-characteristics scope.
- Limitations
- Not diagnostic or a substitute for full evaluation; DBT images and 2D synthetic views are excluded; exact broader device compatibility is unknown.
Exact FDA limitation boundary.
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
- FDA submission
- K220080
- Modality
- Mammography/DBT
Controlled catalog bucket retained; exact FDA scope is 2D FFDM screening mammography, excluding DBT and 2D synthetic views.
- Anatomy
- Breast
FDA comparison-table body part.
- Clearance type
- 510(k)
- Decision date
- 2022-09-29
- FDA status
- FDA-cleared
Implementation
Questions for IT, informatics, and operations
Use these fields to structure a vendor demo, security review, and implementation estimate.
- Integration
- The exact-submission ACR model card explicitly references PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
- Deployment and data flow
- Both
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
- Security and privacy
- Vendor documentation pending
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Training and support
- Vendor documentation pending
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Monitoring and change control
- Vendor documentation pending
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Supported acquisition environment
Scanner manufacturers: All
exact submission · checked 2026-09-01Confirm currently supported software versions, protocols, and site-specific acquisition configurations.
ACR exact-submission catalog context
ACR AI Central provides an exact-submission model card for CogNet QmTRIAGE; FDA labeling remains controlling for clinical use, limitations, and performance.
exact submission · checked 2026-09-09Evidence
Performance evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
- Evidence summary
- FDA packet reports 800 retrospective anonymized 2D FFDM exams, 399 biopsy-proven cancer and 401 negative BI-RADS 1/2 cases; AUROC 0.9569 (95% CI 0.9364-0.9738), sensitivity 87%, and specificity 89%. Accuracy 95.6% is not reported.
Submission-reported retrospective validation; no subgroup breakdown.
- Reported sensitivity
- 87%
Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.
- Reported specificity
- 89%
Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
CogNet QmTRIAGE regulatory performance study summary
- DesignStand-Alone Performance
- PopulationPopulation described in the exact-submission ACR model card
- Scopeexact submission
- Tested versionExact product version not reported; regulatory study summarized for FDA submission K220080
- Samplen=800
- IndependenceIndependence not established
K220080
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Costs and setup
Budget and ongoing governance
These are common procurement questions; unknown values remain visible until a source supports them.
- Pricing and total cost
- Vendor documentation pending
No public price or quote for the exact K220080 configuration was established in this review.
- Reimbursement and coding
- Not established in reviewed sources
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
- Postmarket safety review
- The exact-identifier FDA recall query returned no native recall record for K220080. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Buyer worksheet
Open questions to take to the vendor
- Verify security and privacy controls: Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Verify training: Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Verify pricing and total cost: No public price or quote for the exact K220080 configuration was established in this review.
- Verify reimbursement and coding relevance: No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
- Verify local validation and lifecycle monitoring: Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Research record
What has been checked
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Sources & history
How this profile was documented
Open the ledger for source dates, scope, and research-record updates.
View source ledger and history
Source ledger
-
FDA K220080: CogNet QmTRIAGE
Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary
-
Artificial Intelligence-Enabled Medical Devices
Scope: regulatoryIdentity, modalityContext
-
CogNet QmTRIAGE model card (K220080)
Scope: intendedUsers, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
-
PubMed biomedical literature index
Scope: evidenceDiscovery
-
ClinicalTrials.gov study registry
Scope: evidenceDiscovery, studyStatus
-
openFDA Device Recall API
Scope: recallDiscovery, nativeSubmissionMatching
-
openFDA exact recall query for K220080
Scope: postmarketSafety
Research history
-
K220080 FDA decision
Regulatory record
510(k)
-
Source-review record updated
Research record
fda record reviewed
-
Reader overview source-reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Related tools to compare
FDA-cleared K252954
MammoSightAI
Neurocareai, Inc. (Dba Savelife.Ai)
Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
- Modality
- Mammography/DBT
- Anatomy
- Breast
- Decision
- 2026-05-04
FDA-cleared K252482
CogNet AI-MT+
Medcognetics, Inc.
Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.
- Modality
- Mammography/DBT
- Anatomy
- Breast
- Decision
- 2025-12-11
FDA-cleared K233108
VinDr-Mammo
VinBigData Joint Stock Company
The VinDr-Mammo is a passive notification for prioritization-only, a parallel- workflow software tool used by MQSA qualified interpreting physicians to prioritize patients with...
- Modality
- Mammography/DBT
- Anatomy
- Breast
- Decision
- 2024-05-23
FDA-cleared K203517
Saige-Q
DeepHealth, Inc.
Provides passive worklist prioritization for compatible FFDM and DBT screening mammograms.
- Modality
- Mammography/DBT
- Anatomy
- Breast
- Decision
- 2021-04-16